Navigation Links
Alnylam and Stanford University Scientists Discover New Role for,microRNAs (miRNAs) in T Cell Biology and Immunity

i, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was recognized for its potential broad impact in medicine with the award of the 2006 Nobel Prize for Physiology or Medicine. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause targeted gene silencing.

About microRNA (miRNA)

RNAi can also be induced by microRNAs, or miRNAs, that occur naturally within all mammalian cells. The miRNA molecules are encoded by the cell's own genes, giving rise to small RNA molecules that are similar in structure to siRNAs. There are believed to be over 250 confirmed miRNA genes in the human genome and there are many other predicted miRNAs. miRNAs are thought to work through RNAi to regulate the activity of an estimated one-third of genes in the genome. The inappropriate absence or presence of specific miRNA molecules in various cells has been shown to be associated with specific human diseases, including cancer and viral infections.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I hum
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
5. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
6. Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher
7. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
8. Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds
9. Stanford Study Finds No Conclusive Benefit From Treating Kleptomania With Medication
10. Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says
11. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
Post Your Comments:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
(Date:11/26/2014)... Nov. 25, 2014 Immune Pharmaceuticals Inc. ... stage biopharmaceutical company that engages in the development ... of inflammatory diseases and cancer, today announced the ... of 3,450,000 units, with each unit consisting of ... value $0.0001 per share, and one warrant to ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company ... purification, today reported that the U.S. Food and Drug Administration has issued ... , , ... final decision letter from the FDA for the company,s 510(k) submission which ...
... July 7 ICAP ... division of ICAP plc (IAP.L), is offering for ... drug formulation technology Captisol® owned by CyDex Pharmaceuticals ... fifteen related foreign counterparts covering two important close-to-market, ...
Cached Medicine Technology:Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 2Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 3Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 4ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 2ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 3
(Date:11/26/2014)... 26, 2014 The family foundation of ... the Mesothelioma Applied Research Foundation (Meso Foundation), half of ... Patient Travel Grant Program . The focus area ... create grant partnerships with organizations that can generate transformational ... Schulze is the founder and chairman emeritus of Best ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... For those with a New Year’s resolution to get ... at the University of Colorado Anschutz Health and Wellness ... The 45- 60 minute classes have just started and are ... club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition ... at fast results , By focusing on low weight ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in sustainable financial improvement ... ended June 30, 2009. , , Financial Highlights , ... in the year totaling $43.2m (FY08: $25.7m), 68% up from the previous year, contributing ... to $23.0m (FY08: $18.7m) , 51% ...
... , , WASHINGTON, Sept. 8 More ... in scrubs and lab coats this week to bring an angry message ... The doctors, all traveling as individuals and at their own expense, will ... meet with the doctors of Congress, including Tom Price, M.D. (GA) and ...
... , , , ... and Walmart,s Leslie Dach to discuss areas of bipartisan agreement in ... The Bipartisan Policy Center (BPC) and Better Health Care Together ... agreement among political, business and labor leaders in the health reform ...
... maintained in mice given HDAC inhibitors, study finds , TUESDAY, ... cancer drug might be able to restore day-to-day memory ... common form of dementia among the elderly, is expected to ... sign is loss of short-term memory. , "People often joke ...
... , BRISTOL, Va. and BIRMINGHAM, Ala., ... (NYSE: HLS ) today announced that a joint venture ... of public need (COPN) to open a new inpatient rehabilitation hospital ... Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality ...
... , NEW YORK, Sept. 8 ... its catalogue. , , Lung Cancer ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , This report ... Millions of US$. The US market for Non-Small Cell Lung Cancer ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Dr. 'Smith' Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10 2Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10